Efficient Preparation of 2,2'-Disubstituted-3,3'-(1, 4-phenylene)bisthienopyrimidin-4-ones Based on an aza-Wittig Reaction

Kai Yan, Hong Chen, Qiuhong Dai, and Mingguo Liu*

Hubei Key Laboratory of Natural Products Research and Development, China Three Gorges University, Yichang, 443002,

People's Republic of China *E-mail: mgliu0427@yahoo.com.cn

Received August 25, 2011 DOI 10.1002/jhet.1579

Published online 27 June 2013 in Wiley Online Library (wileyonlinelibrary.com).



Tandem aza-Wittig reaction of iminophosphorane with 1,4-phenylene diisocyanate followed by intramolecular heteroconjugate addition annulation after addition of a nucleophilic reagent (amine, phenol, and alcohol), in the presence of catalytic K₂CO₃ or NaOR, gives selectively the functionalized substituted 2,2'-di(alkylamino, aryloxy)-3,3'-(1, 4-phenylene)bis(thieno[3,2-d]pyrimidin-4(3H)-ones) and 2,2'-di(alkylamino or alkoxy)-3,3'-(1, 4-phenylene)bis(3,5,6,7-tetrahydro-4H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-ones).

J. Heterocyclic Chem., 50, 850 (2013).

INTRODUCTION

The development of efficient and mild synthetic methods for heterocyclic compounds represents a broad area of organic chemistry. In recent years, the aza-Wittig reactions of iminophosphoranes have received increased attention in view of their utility in the synthesis of heterocyclic compounds, especially nitrogen-containing heterocyclic compounds [1]. The intermolecular aza-Wittig reaction followed by cyclizing has been utilized for the synthesis of many important nitrogen heterocycles [2]. Especially thienopyrimidine derivatives, they are an important class of S-heterocyclic and N-heterocyclic compounds in pharmaceutical discovery research because of their significant activities such as anticancer, antifungal, and antibacterial activities [3-6].

Iminophosphoranes-containing thiophene ring, derived from aminothiophene, have proved to be very versatile building blocks for the construction of fused thienopyrimidine system by the aza-Wittig reaction. We have previously published the synthesis of fused thienopyrimidines on the basis of the tandem aza-Wittig reaction. As a continuation of our work on the aza-Wittig-type methodology, we report here a simple, general, and effective strategy for the preparation of substituted derivatives of 2, 2'-di (alkylamino, aryloxy)-3, 3'-(1, 4-phenylene)bis(thieno[3, 2-d]pyrimidin-4(3H)-ones) and 2, 2'-di(alkylamino, alkoxy)-3, 3'-(1, 4-phenylene)bis(3, 5, 6, 7-tetrahydro-4H-cyclopenta [4, 5]thieno[2, 3-d]pyrimidin-4-ones).

RESULTS AND DISCUSSION

In recent years, our work has been concerned with the discovery and development of synthesis of new heterocyclic compounds containing thienopyrimidine moiety. We have previously reported on the synthesis of novel tricyclic ring systems, containing the thienopyrimidine skeleton, with antibacterial and antifungal activities [7]. Among them, 3, 3'-diphenyl-2, 2'-(1, 3-phenylenedioxy)bis(3, 5, 6, 7-tetrahydro-4*H*-cyclopenta[4, 5]thieno[2, 3-*d*]pyrimidin-4-ones), because of two connected thienopyrimidine, showed significant activity of anticitrinin [8]. We now describe here, as a further extension of the aza-Wittig-type methodology, the synthesis of connected thienopyrimidines.

Heterocyclic compounds 5a-g and 6a-g were obtained in a reaction of the corresponding iminophosphoranes with aromatic isocyanates, followed by heterocyclization on addition of amines, phenol, or alcohol.

The key iminophosphoranes 2a-b were obtained by a modified Kirsanov reaction of the aminothiophene 1a-b with in situ prepared dichlorotriphenylphosphorane using a hexachloroethane-triphenylphosphine-triethylamine reagent system (Scheme 1). The molecular structure of iminophposphoranes was supported by the spectral data and elemental analysis.

Iminophosphorane 2 reacted with half equiv of 1,4-Phenylene Diisocyanate (PPDI) to give carbodiimide 3, which was allowed to react with amine to provide guanidine intermediates 4. In the presence of a catalytic amount of sodium ethoxide, 4 were converted easily to substituted 5a-e at room temperature. While the formation of products 5f-g were carried out by heterocyclization on addition of phenols in the presence of K₂CO₃ (Scheme 2)

Owing to the unstability of carbodiimide **3**, the preparation of carbodiimides **3** must be carried out at low temperature $(0-5^{\circ}C)$ and long reaction time (8-l2 h) under dry conditions. Otherwise, hydrolysis or polymerization side reaction of carbodiimide should take place, which will result in low yields [9].

The participation of carbodiimide **3** and the corresponding guanidine-type compound **4** as intermediates in this process has been confirmed experimentally [10].





Moreover, we considered the possibility of extending this design strategy to the preparation of 2, 2'-di(alkylamino or alkoxy)-3, 3'-(1, 4-phenylene)bis(3, 5, 6, 7-tetrahydro-4*H*-cyclopenta[4, 5]thieno[2, 3-*d*]pyrimidin-4-ones) **6**. We reacted 1, 4-phenylene diisocyanate with iminophosphorane **2b**, under similar reaction conditions, which furnished new compounds **6** (Scheme 3).

EXPERIMENTAL

Measurements. Melting points were uncorrected. Mass spectra were measured on a Finnigan Trace MS spectrometer (California, USA). ¹H and ¹³C NMR spectra were recorded in CDCl₃ on Varian (California, USA) Mercury 600 and 400 spectrometers, and resonances were given in δ relative to TMS. Elementary analyses were carried out on a Vario EL III elementary analysis instrument.

Preparation of iminophosphorane 2. To a mixture of aminothiophene **1** (8 mmol), PPh₃ (3.14 g, 12 mmol), and C₂Cl₆ (2.84 g, 12 mmol) in dry MeCN (40 mL) was added dropwise NEt₃ (2.42 g, 24 mmol) at room temperature. After stirring for 4 h, the solvent was removed under reduced pressure, and the residue was recrystallized from EtOH to give methyl 3-[(triphenylphosphoranylidene)amino]thiophene-2-carboxylate **2a** or ethyl 2-[(triphenylphosphoranylidene)amino]-5, 6-dihydro-4*H*-cyclopenta[*b*]thiophene-3-carboxylate **2b**.

2a: White crystals (yield 71%). mp: 115–117°C; ¹H NMR (CDCl₃, 400 MHz) δ (ppm): 7.82–7.45 (m, 15H, Ar-H), 7.03 (d, *J*=5.2 Hz, 1H, Ar-H), 6.20 (d, *J*=5.2 Hz, 1H, Ar-H), 3.84 (s, 3H, OCH₃); ¹³C NMR (CDCl₃, 100 MHz) δ (ppm): 163.8, 156.0, 132.5, 131.8, 130.9, 129.9, 129.3, 129.1, 128.7, 128.5, 128.3, 124.7, 50.8; MS *m*/*z* (%): 417 (M⁺, 86), 384 (43), 358 (100), 183 (66), 77 (87), 59 (59); *Anal.* Calcd for C₂₄H₂₀NO₂PS: C, 69.05; H, 4.83; N, 3.36. Found C, 69.29; H, 4.61; N, 3.59.

2b: Yellow solid (yield 86%). mp: 183–184°C. ¹H NMR (CDCl₃, 400 MHz) δ (ppm): 7.47–7.88 (m, 15H, Ar-H), 4.27 (q, *J*=6.8 Hz, 2H, OCH₂), 2.88 (t, *J*=6.4 Hz, 2H, CH₂), 2.59

Scheme 2. Preparation of compounds 5a-g.



5g: Y=3-(trifluoromethyl)phenoxy

Scheme 3. Preparation of compounds 6a-g.



(t, J=6.4 Hz, 2H, CH₂), 2.19 (m, 2H, CH₂), 1.34 (t, J=6.8 Hz, 3H, CH₃); MS *m/z*: 471 (M⁺, 79); *Anal.* Calcd for C₂₈H₂₆NO₂PS: C, 71.32; H, 5.56; N, 2.97. Found: C, 71.55; H, 5.32; N, 3.21.

General procedure of 2, 2'-dialkylamino-3, 3'-(1, 4-phenylene) bis(thieno[3, 2-d]pyrimidin -4(3H)-ones) 5a–e. To a solution of iminophosphorane 2a (0.84 g, 2 mmol) in dry CH₂Cl₂ (5 mL) was added 1, 4-phenylene diisocyanate (1 mmol) at room temperature. Then, the reaction mixture was left to stand for 8– 12 h at 0–5°C until the iminophosphorane had disappeared (TLC monitored). To the solution prepared earlier was added amine (2 mmol). After the reaction mixture was allowed to stand for 0.5–6 h (TLC monitored), the solvent was removed, and anhydrous ethanol (10 mL) with several drops of EtONa in EtOH was added. The solution was then concentrated under reduced pressure, and residual was recrystallized from CH₂Cl₂ and EtOH (1:2) to give compounds 5a–f.

5a: 2, 2'-Di(dipropylamino)-3, 3'-(1, 4-phenylene)bis(thieno [3, 2-d]pyrimidin-4 (3H)-one). White crystals (yield 51%). mp: 248°C. ¹H NMR (CDCl₃, 400 MHz) δ (ppm): 7.74–7.18 (m, 8H, Ar-H), 3.01 (t, J=7.8 Hz, 8H, NCH₂), 1.35 (m, 8H, CH₂), 0.78 (t, J=7.4 Hz, 12H, CH₃); ¹³C NMR (CDCl₃, 150 MHz) δ (ppm): 159.2, 156.9, 156.8, 137.4, 134.5, 129.5, 124.6, 116.9, 53.0, 20.7, 11.6; Anal. Calcd for C₃₀H₃₆N₆O₂S₂: C, 62.47; H, 6.29; N, 14.57. Found: C, 62.69; H, 6.01; N, 14.79.

5b: 2, 2'-Di(diisopropylamino)-3, 3'-(1, 4-phenylene)bis(thieno [3, 2-d]pyrimidin-4 (3H)-one). White crystals (yield 52%). mp: $>300^{\circ}$ C. ¹H NMR (CDCl₃, 600 MHz) δ (ppm): 7.72–7.16 (m, 8H, Ar-H), 3.55 (m, 4H, 4NCH), 1.13 (d, 24H, 8CH₃); ¹³C NMR (CDCl₃, 150 MHz) δ (ppm): 159.8, 156.7, 155.4, 138.0, 134.2, 129.8, 124.8, 117.2, 50.2, 21.6; MS *m/z* (%): 576 (M⁺, 2), 367 (17), 277(17), 210 (43), 151 (100), 100 (48); *Anal.* Calcd for C₃₀H₃₆ N₆O₂S₂: C, 62.47; H, 6.29; N, 14.57. Found: C, 62.71; H, 6.02; N, 14.79.

5c: 2, 2'-Di(dibutylamino)-3, 3'-(1, 4-phenylene)bis(thieno[3, 2-d]pyrimidin-4(3H) -one). White crystals (yield 49%). mp: 174–176°C. ¹H NMR (CDCl₃, 400 MHz) δ (ppm): 7.74–7.18 (m, 8H, Ar-H), 3.04 (t, J=7.4 Hz, 8H, 4NCH₂), 1.33–1.16 (m, 16H, 8CH₂), 0.86(t, J=7.2 Hz, 12H, 4CH₃); ¹³C NMR (CDCl₃, 150 MHz) δ (ppm): 159.0, 156.7, 156.6, 137.1, 134.4, 129.2, 124.5, 116.7, 50.8, 29.3, 20.2, 13.7; MS *m/z* (%): 632 (M⁺, 4), 380 (20), 151 (42), 125 (29), 57 (65), 41 (100); Anal. Calcd for C₃₄H₄₄N₆ O₂S₂: C, 64.52; H, 7.01; N, 13.28. Found: C, 64.79; H, 6.78; N, 13.54. *5d:* 2, 2'-*Di*(*diisobutylamino*)-3, 3'-(1, 4-phenylene)bis(thieno [3, 2-*d*]*pyrimidin-4* (3*H*)-*one*). White crystals (yield 47%). mp >300°C. ¹H NMR (CDCl₃, 400 MHz) δ (ppm): 7.73–7.15 (m, 8H, Ar-H), 2.91 (d, *J*=7.2 Hz, 8H, 4NCH₂), 1.86 (m, 4H, 4CH), 0.81 (m, 24H, 8CH₃); ¹³C NMR (CDCl₃, 150 MHz) δ (ppm): 159.0, 157.0, 156.4, 137.3, 134.5, 129.1, 124.4, 116.0, 58.5, 27.1, 20.5; MS *m*/*z* (%): 632 (M⁺, 14), 589 (100), 533 (71), 477 (56), 366 (35), 207 (34), 151 (90); *Anal.* Calcd for C₃₄H₄₄N₆O₂S₂: C, 64.52; H, 7.01; N, 13.28. Found: C, 64.79; H, 6.77; N, 13.59.

6g: Y=n-propoxy

5e: 2, 2'-Di(dihexylamino)-3, 3'-(1, 4- phenylene)bis(thieno [3, 2-d]pyrimidin-4 (3H)-one). White crystals (yield 39%). mp: 100–101°C. ¹H NMR (CDCl₃, 600 MHz) δ (ppm): 7.73– 7.18 (m, 8H, Ar-H), 3.03 (t, J=7.8 Hz, 8H, 4NCH₂), 1.35–1.15 (m, 32H, 16CH₂), 0.85 (t, J=6.6 Hz, 12H, 4CH₃); ¹³C NMR (CDCl₃, 150 MHz) δ (ppm): 159.0, 156.8, 156.6, 137.2, 134.5, 129.1, 124.5, 116.7, 51.0, 31.4, 27.2, 26.7, 22.5, 14.0; MS *m/z* (%): 744 (M⁺, 26), 674 (41), 493 (100), 436 (88), 250 (36), 151 (34); *Anal.* Calcd for C₄₂H₆₀N₆O₂S₂: C, 67.70; H, 8.12; N, 11.28. Found: C, 67.95; H, 7.92; N, 11.53.

General procedure of 2, 2'-diaryloxy-3, 3'-(1, 4-phenylene)bis (thieno[3, 2-d]pyrimidin -4(3H)-ones) 5f-g. To a solution of iminophosphorane 2a (0.84 g, 2 mmol) in dry CH₂Cl₂ (5 mL) was added 1, 4-phenylene diisocyanate (1 mmol) at room temperature. Then, the reaction mixture was left to stand for 8–12 h at 0–5°C until the iminophosphorane had disappeared (TLC monitored). The solvent was evaporated, and the residue was dissolved in MeCN (3 mL), a catalytic amount of K₂CO₃ was added, and the mixture was refluxed for 5 h (TLC monitored) then filtered off. The filtrate was then concentrated under reduced pressure, and residue was recrystallized from CH₂Cl₂ and EtOH (1:2) to give compounds **5f-g**.

5*f*: 2, 2'-Di[4-(methylthio)phenoxy]-3, 3'-(1, 4-phenylene)bis (thieno[3, 2-d] pyrimidin-4(3H) -one). White crystals (yield 45%). mp: 190–192°C. ¹H NMR (CDCl₃, 600 MHz) δ (ppm): 7.77–7.09 (m, 16H, Ar-H), 2.49 (s, 6H, 2SCH₃); MS m/z (%): 654 (M⁺, 14), 268 (17), 247 (31), 200 (27), 139 (100), 111 (29), 96 (74); Anal. Calcd for C₃₂H₂₂N₄O₄S₄: C, 58.70; H, 3.39; N, 8.56. Found: C, 58.95; H, 3.11; N, 8.79.

5g: 2, 2'-Di[3-(trifluoromethyl)phenoxy]-3, 3'-(1, 4-phenylene) bis(thieno[3, 2-d] pyrimidin-4(3H)-one). White crystals (yield 55%). mp >300°C. ¹H NMR (CDCl₃, 600 MHz) δ (ppm): 7.80– 7.13 (m, 16H, Ar-H); MS *m/z* (%): 698 (M⁺, 54), 537 (64), 269 (100), 188 (32), 96 (74); Anal. Calcd for $C_{32}H_{16}F_6N_4O_4\ S_2:\ C,$ 55.01; H, 2.31; N, 8.02. Found: C, 55.27; H, 2.01; N, 8.27.

General procedure of 2, 2'-di(alkylamino)-3, 3'-(1, 4-phenylene)bis(3, 5, 6, 7-tetrahydro -4*H*-cyclopenta[4, 5]thieno[2, 3-*d*]pyrimidin-4-ones) 6a–f. The experimental process is similar to the formation of 2, 2'-dialkylamino-3, 3'-(1, 4-phenylene) bis(thieno[3, 2-*d*]pyrimidin-4(3*H*)-ones) 5a–e.

6a: 2, 2'-Di(dipropylamino)-3, 3'-(1, 4-phenylene)bis(3, 5, 6, 7-tetrahydro-4H-cyclopenta[4, 5]thieno[2, 3-d2]pyrimidin-4ones). White crystals (yield 41%). mp: 253–255.6°C. ¹H NMR (CDCl₃, 600 MHz) δ (ppm): 7.40–7.27 (d, 4H, Ar-H), 2.99–1.35 (m, 28H, 14CH₂), 0.76 (t, J=6.6 Hz, 4CH₃); ¹³C NMR (CDCl₃, 150 MHz) δ (ppm): 168.7, 159.3, 154.3, 140.1, 137.2, 134.3, 129.2, 114.3, 53.4, 52.3, 29.4, 28.9, 27.7, 20.6, 11.5; MS *m*/z (%): 656 (M⁺, 100). *Anal.* Calcd for C₃₁H₃₄N₆O₂S₂: C, 63.45; H, 5.84; N, 14.32; Found: C, 63.69; H, 5.61; N, 14.58.

6b: 2, 2'-Di(diisopropylamino)-3, 3'-(1, 4-phenylene)bis(3, 5, 6, 7-tetrahydro-4H-cyclopenta[4, 5] thieno[2, 3-d]pyrimidin-4-ones). White crystals (yield 69%). mp: 173° C. ¹H NMR (CDCl₃, 600 MHz) δ (ppm): 7.36–7.26 (d, 4H, ArH), 3.53–2.89 (m, 12H, 6CH₂), 2.44–2.39 (m, 4H, 4CH), 0.12–0.11 (d, 24H, 8CH₃); ¹³C NMR (CDCl₃, 150 MHz) δ (ppm): 168.3, 159.9, 153.2, 140.0, 137.8, 134.5, 129.6, 114.7, 50.2, 29.4, 28.9, 27.7, 21.6. MS *m*/*z* (%): 656 (M⁺, 100). *Anal.* Calcd for C₃₁H₃₄N₆O₂S₂: C, 63.45; H, 5.84; N, 14.32; Found: C, 63.68; H, 5.59; N, 14.57.

6c: 2, 2'-Di(dibutylamino)-3, 3'-(1, 4-phenylene)bis(3, 5, 6, 7tetrahydro-4H-cyclopenta[4, 5] thieno[2, 3-d]pyrimidin-4ones). White crystals (yield 48%). mp: 253.8–254.5°C. ¹H NMR (CDCl₃, 600 MHz) δ (ppm): 7.40–7.28 (d, 4H, ArH), 3.03–1.16 (m, 36H, 18CH₂), 0.85 (t, J = 7.2 Hz, 12H, 4CH₃); ¹³C NMR (CDCl₃, 150 MHz) δ (ppm): 168.7, 159.2, 154.3, 140.1, 137.1, 134.3, 129.1, 114.3, 50.9, 29.5, 29.4, 28.9, 27.7, 20.2, 13.7. MS *m*/*z* (%): 712 (M⁺, 100). Anal. Calcd for C₃₃H₃₈N₆O₂S₂: C, 64.47; H, 6.23; N, 13.67; Found: C, 64.71; H, 6.01; N, 13.95.

6d: 2, 2'-Di(diisobutylamino)-3, 3'-(1, 4-phenylene)bis(3, 5, 6, 7-tetrahydro-4H-cyclopenta[4, 5] thieno[2, 3-d]pyrimidin-4ones). White crystals (yield 63%). mp: 269–271°C. ¹HNMR (CDCl₃, 600 MHz) δ (ppm): 7.43–7.26 (d, 4H, Ar-H), 2.99– 2.39 (m, 24H, 12CH₂), 1.84 (s, 4H, 4CH), 0.81–0.79 (d, 24H, 8CH₃); ¹³C NMR (CDCl₃, 150 MHz) δ (ppm): 168.9, 159.1, 154.2, 140.1, 137.3, 133.9, 129.1, 113.8, 58.6, 29.4, 28.9, 27.7, 27.2, 20.5. MS *m/z* (%): 712 (M⁺, 100). Anal. Calcd for C₃₃H₃₈N₆O₂S₂: C, 64.47; H, 6.23; N, 13.67; Found: C, 64.73; H, 6.02; N, 13.91.

6e: 2, 2'-Di(diamylamino)-3, 3'-(1, 4-phenylene)bis(3, 5, 6, 7tetrahydro-4H-cyclopenta[4, 5]thieno[2, 3-d]pyrimidin-4ones). White crystals (yield 41%). mp: 220.3–220.4°C. ¹H NMR (CDCl₃, 600 MHz) δ (ppm): 7.40 (s, 4H, Ar-H), 3.01– 1.12 (m, 44H, 22CH₂), 0.87–0.84 (t, J = 7.2 Hz, 12H, 4CH₃). ¹³C NMR (CDCl₃, 150 MHz) δ (ppm): 168.7, 159.2, 154.2, 140.1, 137.1, 134.2, 129.1, 114.3, 51.1, 29.4, 29.2, 28.9, 27.7, 27.1, 22.2, 13.9. MS *m/z* (%):768 (M⁺, 70). *Anal.* Calcd for C₃₃H₃₈ N₆O₂ S₂: C, 64.47; H, 6.23; N, 13.67; Found: C, 64.76; H, 5.99; N, 13.93. 6f: 2, 2'-Di(n-butylamino)-3, 3'-(1, 4-phenylene)bis(3, 5, 6, 7tetrahydro-4H-cyclopenta[4, 5]thieno[2, 3-d]pyrimidin-4one). White crystals (yield 64%). mp: 270–272°C. ¹H NMR (CDCl₃, 600 MHz) δ (ppm): 7.49(s, 4H, Ar-H), 5.18 (s, 2H, 2NH), 3.37–1.27 (m, 24H, 12CH₂), 0.91–0.89 (t, 6H, 2CH₃); ¹³C NMR (CDCl₃, 150 MHz) δ (ppm): 171.9, 159.2, 150.1, 139.5, 136.2, 131.9, 131.6, 111.4, 41.9, 31.3, 29.4, 29.0, 27.7, 20.0, 13.8; MS *m/z*: 600 (M⁺, 100); Anal. Calcd for C₄₀H₅₂N₆ O₂S₂: C, 67.38; H,7.35;N,11.79. Found: C, 67.59; H, 7.07; N, 12.01.

Synthesis of 2, 2'-dipropoxy-3, 3'-(1, 4-phenylene)bis(3, 5, 6, 7-tetrahydro-4H-cyclopenta[4, 5] thieno[2, 3-d]pyrimidin-4one) 6g. To the solution of carbodiimides prepared earlier in C_3H_7OH (15 mL) was added 1 equiv of C_3H_7ONa in C_3H_7OH . The mixture was stirred for 6 h at room temperature (TLC monitored). The solution was condensed, and the residue was recrystallized from CH_2Cl_2 and EtOH to give 6g. White crystals (yield 61%). mp: 276.6–277.6°C. ¹H NMR (CDCl₃, 600 MHz) δ (ppm): 7.30 (s, 4H, Ar-H), 4.31 (s, 4H, OCH₂), 3.02 (s, 4H, CH_2), 2.93 (s, 4H, CH₂), 2.44 (m, 4H, CH₂), 1.65 (s, 4H, CH₂), 0.84 (s, 6H, CH₃); MS *m/z*: 574 (M⁺, 20); Anal. Calcd for $C_{30}H_{30}$ N₄O₄S₂: C, 62.70; H, 5.26; N, 9.75. Found: C, 62.91; H, 5.05; N, 10.02.

Acknowledgments. We gratefully acknowledge the Science Foundation of Hubei Province Education Department, China (project no. D20091301) and the Excellent Fund for Scientific Research and Special Projects in China Three Gorges University, China (project no. KJ 2009 B004) for the financial support of this work.

REFERENCES AND NOTES

 (a) Zhong, Y.; Wang, L.; Ding, M.-W. Tetrahedron 2011, 67, 3714; (b) Marsden, S. P.; McGonagle, A. E.; McKeever-Abbas, B. Org Lett 2008, 10, 2589; (c) Devarie-Baez, N. O.; Xian, M. Org Lett 2010, 12, 752.

[2] (a) Ding, M. W.; Xu, S. Z.; Zhao, J. F. J. Org Chem 2004, 69, 8366; (b) Zhao, J. F.; Xie, C.; Ding, M. W.; He, H. W. Synthesis 2005, 15, 2544.

[3] Chambhare, R. V.; Khadse, B. G.; Bobde, A. S.; Bahekar, R. H. Eur J Med Chem 2003, 38, 89.

[4] Wang, Y. D.; Johnson, S.; Powell, D.; McGinnis, J. P.; Miranda, M.; Rabindran, S. K. Bioorg Med Chem Lett 2005, 15, 3763.

[5] Jennings, L. D.; Kincaid, S. L.; Wang, Y. D.; Krishnamurthy, G.; Beyer, C. F.; McGinnis, J. P.; Miranda, M.; Discafani, C. M.; Rabindran, S. K. Bioorg Med Chem Lett 2005, 15, 4731.

[6] Al-Omran, F.; El-Khair, A. A. J Heterocyclic Chem 2004, 41, 909.

[7] Liao, Q. B.; Liu, M. G.; Yu, L.; Zhu, M.; Ding, M. W. Chin J Org Chem 2009, 29, 1582.

[8] Liao, Q. B.; Liu, M. G.; Chen, B. L.; Ding, M. W. Chin J Appl Chem 2010, 27, 533.

[9] Liu, M. G.; Zhong, Y.; Ding, M. W. Chem Res Chinese U 2008, 24, 437.

[10] Vazquez, D.; Peinador, C.; Quintela, J. M. Tetrahedron, 2004, 60, 275.